TCG Crossover funds in Vor (VOR) disclose 2,836,539 common shares

Rhea-AI Filing Summary

Vor Biopharma Inc. received an initial insider ownership report from TCG Crossover investment entities. The filing shows indirect holdings of 2,836,539 shares of Vor Biopharma common stock as of March 30, 2026, with TCG Crossover funds and their general partners reported as ten percent owners sharing voting, investment, and dispositive power.

Insider Trade Summary

2 transactions reported

Mixed 2 txns

Insider TCG Crossover GP II, LLC, TCG Crossover Fund II, L.P., TCG Crossover GP III, LLC, TCG Crossover Fund III, L.P.

Role 10% Owner | 10% Owner | 10% Owner | 10% Owner

Type	Security	Shares	Price	Value
holding	Common Stock	--	--	--
holding	Common Stock	--	--	--

Holdings After Transaction: Common Stock — 2,836,539 shares (Indirect, See footnote)

Footnotes (1)

1. These securities are held of record by TCG Crossover Fund II, L.P. (TCG Crossover II). TCG Crossover GP II, LLC (TCG Crossover GP II) is the general partner of TCG Crossover II and may be deemed to have voting, investment, and dispositive power with respect to these securities. Chen Yu is the sole managing member of TCG Crossover GP II and may be deemed to share voting, investment and dispositive power with respect to these securities. These securities are held of record by TCG Crossover Fund III, L.P. (TCG Crossover III). TCG Crossover GP III, LLC (TCG Crossover GP III) is the general partner of TCG Crossover III and may be deemed to have voting, investment, and dispositive power with respect to these securities. Chen Yu is the sole managing member of TCG Crossover GP III and may be deemed to share voting, investment and dispositive power with respect to these securities.

Key Figures

Indirect common shares held: 2,836,539 shares Holding entries: 2 Unknown transaction records: 2 +1 more

4 metrics

Indirect common shares held 2,836,539 shares Total shares following holding entries as of March 30, 2026

Holding entries 2 Number of holding-type records in the Form 3 summary

Unknown transaction records 2 Transactions with unknown direction in transactionSummary

Buy and sell transactions 0 buys, 0 sells No recorded purchases or sales in this filing

Key Terms

ten percent owner, indirect, dispositive power, beneficial ownership

4 terms

ten percent owner regulatory

"each reporting person is identified as a ten percent owner"

indirect financial

"total_shares_following_transaction shows indirect ownership (ownership_type "indirect")"

dispositive power financial

"may be deemed to have voting, investment, and dispositive power with respect to these securities"

Dispositive power is the authority to decide the final outcome of an asset, legal claim, contract, or corporate action — in effect the power to dispose of or resolve something. For investors it matters because whoever holds that authority can determine who gets paid, who controls an asset or vote, and how risks and returns are allocated; think of it like holding the key that lets you lock in the winner or loser in a deal.

beneficial ownership regulatory

"initial statement of beneficial ownership of securities by TCG Crossover entities"

Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.

Understanding Insider Trading Forms →

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

TCG Crossover GP II, LLC

(Last) (First) (Middle)

245 LYTTON AVE., SUITE 350

(Street)

PALO ALTO CALIFORNIA 94301

(City) (State) (Zip)

UNITED STATES

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
03/30/2026

3. Issuer Name and Ticker or Trading Symbol
Vor Biopharma Inc. [ VOR ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	X	10% Owner
	Officer (give title below)		Other (specify below)

6. Individual or Joint/Group Filing (Check Applicable Line)

	Form filed by One Reporting Person
X	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock	2,836,539	I	See footnote(1)
Common Stock	2,836,539	I	See footnote(2)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

1. Name and Address of Reporting Person^*

TCG Crossover GP II, LLC

(Last) (First) (Middle)

245 LYTTON AVE., SUITE 350

(Street)

PALO ALTO CALIFORNIA 94301

(City) (State) (Zip)

UNITED STATES

(Country)

Relationship of Reporting Person(s) to Issuer

	Director	X	10% Owner
	Officer (give title below)		Other (specify below)

1. Name and Address of Reporting Person^*

TCG Crossover Fund II, L.P.

(Last) (First) (Middle)

245 LYTTON AVE., SUITE 350

(Street)

PALO ALTO CALIFORNIA 94301

(City) (State) (Zip)

UNITED STATES

(Country)

Relationship of Reporting Person(s) to Issuer

	Director	X	10% Owner
	Officer (give title below)		Other (specify below)

1. Name and Address of Reporting Person^*

TCG Crossover GP III, LLC

(Last) (First) (Middle)

245 LYTTON AVE., SUITE 350

(Street)

PALO ALTO CALIFORNIA 94301

(City) (State) (Zip)

UNITED STATES

(Country)

Relationship of Reporting Person(s) to Issuer

	Director	X	10% Owner
	Officer (give title below)		Other (specify below)

1. Name and Address of Reporting Person^*

TCG Crossover Fund III, L.P.

(Last) (First) (Middle)

245 LYTTON AVE., SUITE 350

(Street)

PALO ALTO CALIFORNIA 94301

(City) (State) (Zip)

UNITED STATES

(Country)

Relationship of Reporting Person(s) to Issuer

	Director	X	10% Owner
	Officer (give title below)		Other (specify below)

Explanation of Responses:

1. These securities are held of record by TCG Crossover Fund II, L.P. (TCG Crossover II). TCG Crossover GP II, LLC (TCG Crossover GP II) is the general partner of TCG Crossover II and may be deemed to have voting, investment, and dispositive power with respect to these securities. Chen Yu is the sole managing member of TCG Crossover GP II and may be deemed to share voting, investment and dispositive power with respect to these securities.

2. These securities are held of record by TCG Crossover Fund III, L.P. (TCG Crossover III). TCG Crossover GP III, LLC (TCG Crossover GP III) is the general partner of TCG Crossover III and may be deemed to have voting, investment, and dispositive power with respect to these securities. Chen Yu is the sole managing member of TCG Crossover GP III and may be deemed to share voting, investment and dispositive power with respect to these securities.

	/s/ TCG Crossover GP II, LLC /s/ Craig Skaling, Authorized Signatory	04/01/2026
	/s/ TCG Crossover Fund II, L.P. /s/ Craig Skaling, Authorized Signatory	04/01/2026
	/s/ TCG Crossover GP III, LLC /s/ Craig Skaling, Authorized Signatory	04/01/2026
	/s/ TCG Crossover Fund III, L.P. /s/ Craig Skaling, Authorized Signatory	04/01/2026
	/s/ Craig Skaling, as Attorney-in-Fact for Chen Yu	04/01/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)

FAQ

What does the Vor Biopharma (VOR) Form 3 filing show about insider ownership?

The Form 3 shows that TCG Crossover investment entities are ten percent owners of Vor Biopharma, reporting indirect holdings of 2,836,539 common shares as of March 30, 2026. These holdings are reported through limited partnerships and their general partners.

Who are the reporting persons in Vor Biopharma (VOR)'s Form 3 filing?

The reporting persons are TCG Crossover GP II, LLC, TCG Crossover Fund II, L.P., TCG Crossover GP III, LLC, and TCG Crossover Fund III, L.P.. Each is identified as a ten percent owner of Vor Biopharma Inc.

How many Vor Biopharma (VOR) shares are reported in this insider ownership statement?

The filing reports indirect ownership of 2,836,539 shares of common stock. This figure appears as the total shares beneficially owned following the reported holdings, giving investors a snapshot of the TCG Crossover position in Vor Biopharma.

How are the Vor Biopharma (VOR) shares held by the TCG Crossover entities structured?

According to the footnotes, shares are held of record by TCG Crossover Fund II, L.P. and TCG Crossover Fund III, L.P., with their respective general partners, TCG Crossover GP II, LLC and TCG Crossover GP III, LLC, having voting, investment, and dispositive power over the securities.

Does the Vor Biopharma (VOR) Form 3 indicate any recent insider buying or selling?

No buying or selling is indicated. The Form 3 shows holding entries only, with transaction direction marked as unknown and zero recorded buy, sell, or exercise transactions. It functions as an initial statement of beneficial ownership rather than a trade report.